2004
DOI: 10.1074/jbc.m401803200
|View full text |Cite
|
Sign up to set email alerts
|

A Neutralizing Anti-Nogo66 Receptor Monoclonal Antibody Reverses Inhibition of Neurite Outgrowth by Central Nervous System Myelin

Abstract: The Nogo66 receptor (NgR1) is a neuronal, leucinerich repeat (LRR) protein that binds three central nervous system (CNS) myelin proteins, Nogo, myelinassociated glycoprotein, and oligodendrocyte myelin glycoprotein, and mediates their inhibitory effects on neurite growth. Although the LRR domains on NgR1 are necessary for binding to the myelin proteins, the exact epitope(s) involved in ligand binding is unclear. Here we report the generation and detailed characterization of an anti-NgR1 monoclonal antibody, 7E… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

4
42
1

Year Published

2005
2005
2015
2015

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 59 publications
(47 citation statements)
references
References 34 publications
(45 reference statements)
4
42
1
Order By: Relevance
“…In addition, the Nogo receptor LRR domain has been implicated in trans interactions. Similar to our data indicating that an antibody to the SALM LRR domain inhibits SALM4 trans-cellular associations, a monoclonal antibody to the third LRR of Nogo receptor reverses the inhibition of neurite outgrowth by myelin and blocks binding of the Nogo receptor ligands Nogo, myelinassociated glycoprotein, and oligodendrocyte-myelin glycoprotein (59).…”
Section: Discussionsupporting
confidence: 90%
“…In addition, the Nogo receptor LRR domain has been implicated in trans interactions. Similar to our data indicating that an antibody to the SALM LRR domain inhibits SALM4 trans-cellular associations, a monoclonal antibody to the third LRR of Nogo receptor reverses the inhibition of neurite outgrowth by myelin and blocks binding of the Nogo receptor ligands Nogo, myelinassociated glycoprotein, and oligodendrocyte-myelin glycoprotein (59).…”
Section: Discussionsupporting
confidence: 90%
“…In part, cell-intrinsic programs limit axonal regeneration (Liu et al, 2011). In addition, the adult CNS is an inhibitory environment due to the expression of chondroitin sulfate proteoglycans (Yiu and He, 2006) and myelin-associated inhibitors (NogoA, myelin-associated glycoprotein, oligodendrocyte myelin glycoprotein; Akbik et al, 2012).…”
Section: Introductionmentioning
confidence: 99%
“…These molecules restrict axon growth by signaling through neuron-specific Nogo Receptors 1 and 3 (NgR1, (Fournier et al, 2001;Dickendesher et al, 2012), PirB (Atwal et al, 2008), PTPsigma (Shen et al, 2009;Fry et al, 2010), leukocyte common antigen-related phosphatase (Fisher et al, 2011), and the sphingolipid receptor S1PR2 (Kempf et al, 2014). Receptor antagonism via either genetic perturbation Simonen et al, 2003;Kim et al, 2004;Dimou et al, 2006;Cafferty et al, 2010;Dickendesher et al, 2012;Bartus et al, 2014) or pharmacological treatment (Schnell and Schwab, 1990;Bradbury et al, 2002;GrandPré et al, 2002;Liebscher et al, 2005;Wang et al, 2006;Wang et al, 2011;Lang et al, 2015) results in enhanced (yet incomplete) recovery of motor function after experimental SCI (Basso et al, 1995;Basso et al, 2006). In general, the anatomical substrate supporting functional recovery remains unclear and correlative.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…The discovery of an anti-NgR monoclonal antibody, capable of inhibiting binding of Nogo, MAG, and OMgp, and of blocking inhibition of myelin in vitro, has now been reported. 54 Downstream of NgR are several other molecules that might also serve as targets for intervention after SCI. The Nogo receptor is thought to transmit myelininhibitory signaling through its interaction with the low-affinity neurotrophin receptor p75.…”
Section: Myelin and Myelin Signaling: An Inhibitory Chorus Linementioning
confidence: 99%